Pharmaceutical company Mallinckrodt plc (OTCMKTS: MNKTQ) on Wednesday announced the presentation of 11 scientific abstracts at the American Association for the Study of Liver Diseases (AASLD) 2023 Liver Meeting. The data focuses on TERLIVAZ (terlipressin) for injection in adult patients with hepatorenal syndrome (HRS) involving rapid reduction in kidney function. The event is scheduled for 10-14 November 2023 in Boston, MA.

Included are three oral presentations and one AASLD Poster of Distinction, detailing clinical outcomes and real-world health economics findings for TERLIVAZ-treated patients with comorbidities.

TERLIVAZ is reportedly the only FDA-approved product for improving kidney function in adults with HRS involving rapid reduction in kidney function, affecting over 35,000 Americans annually.

Key highlights of Mallinckrodt's presentations include a pooled analysis of prospective studies evaluating TERLIVAZ's safety and efficacy in HRS type 1 patients, health economics outcomes in alcohol-related cirrhosis and HRS, and an analysis of clinical outcomes with concomitant albumin dosing.

Mallinckrodt's presence at the AASLD 2023 Liver Meeting also includes an interactive Medical Affairs booth in the exhibit hall (Location D2825) throughout the event.